Aurinia Pharmaceuticals (AUPH) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Perrigo (PRGO) over the past year, gaining 36.7% versus a loss of 32.9%. Over five years, AUPH leads with a -22.2% price change compared with -67.5% for PRGO. Aurinia Pharmaceuticals is the larger company by market cap ($2.13 billion vs $2.01 billion), about 1.1 times the size.
On valuation, Perrigo trades at a lower forward P/E (6.1x vs 15.0x for Aurinia Pharmaceuticals). Perrigo pays a dividend yielding 7.97%, while Aurinia Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | PRGO |
|---|---|---|
| Share price | $16.01 | $14.55 |
| Market cap | $2.13B | $2.01B |
| 1-day change | +2.04% | +3.93% |
| YTD return | +0.38% | +4.53% |
| 1-year return | +36.72% | -32.89% |
| 5-year return | -22.17% | -67.46% |
| P/E ratio (TTM) | 7.02 | — |
| Forward P/E | 15.01 | 6.07 |
| EPS (TTM) | $2.28 | $-12.28 |
| Dividend yield | 0.00% | 7.97% |
| Annual dividend | $0.00 | $1.16 |
| 52-week high | $19.25 | $22.02 |
| 52-week low | $10.90 | $9.23 |
| Distance from 52-week high | -16.83% | -33.92% |
| Analyst consensus | none | none |
| Avg. price target upside | +11.56% | +13.40% |
| Average volume | 1.01M | 2.81M |
| Shares outstanding | 133.05M | 138.37M |
| Employees | 128 | 8,100 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed PRGO by 69.6 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.97% vs 0.00%).
- The two companies sit in different sectors: Aurinia Pharmaceuticals in Healthcare and Perrigo in Health Care.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Healthcare · Biotechnology · 128 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
AUPH vs PRGO FAQ
Which is bigger, Aurinia Pharmaceuticals or Perrigo?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.13B compared with $2.01B for Perrigo (PRGO).
Which stock has performed better over the past year, AUPH or PRGO?
AUPH returned +36.72% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Aurinia Pharmaceuticals or Perrigo?
Perrigo pays a dividend yielding 7.97%, while Aurinia Pharmaceuticals does not currently pay a regular dividend.
Are Aurinia Pharmaceuticals and Perrigo in the same industry?
No. Aurinia Pharmaceuticals is in the Healthcare sector, while Perrigo is in Health Care.